\u201cWe are honored to be selected by ACR to present our late-breaking Phase 2b data for rosnilimab in RA,\u201d said Paul Lizzul, chief medical officer of Anaptys. \u201cBeing selected reinforces the transformational potential of rosnilimab, which delivered a compelling safety and tolerability profile and JAK-like efficacy through six months that was durable for at least three months off-drug. We look forward to Professor Emery\u2019s presentation later this month.\u201d<\/p>\n
Presentation Details:<\/p>\n
Abstract Title \u2013 Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2b TrialAbstract ID – 2215555Session Date and Time – Wednesday, Oct. 29 from 8:00am \u2013 9:30am CT <\/p>\n
Paul Emery, M.D., professor, Rheumatology, University of Leeds, \u200bLeeds Biomedical Research Centre, U.K., will be the presenting author.<\/p>\n
The presentation will be available for download on the Anaptys website after the session\u00a0here<\/a>.<\/p>\n About Rosnilimab<\/p>\n Rosnilimab is a novel therapeutic antibody that directly targets pathogenic T cells, such as activated Tph\/Tfh and T effector cells, in the periphery or inflamed tissue. When activated, these T cells proliferate and migrate and secrete inflammatory cytokines that are the drivers of autoimmune and inflammatory diseases.<\/p>\n Rosnilimab is designed to selectively and potently deplete pathogenic T cells in both inflamed tissue and the periphery while sparing nonpathogenic T cells, including na\u00efve T cells, to preserve overall immune function and restore immune homeostasis. This drives specific immunological outcomes, such as a reduction in T cell proliferation, migration and cytokine secretion, and a reduction of plasma cell generation and autoantibody levels.<\/p>\n About Anaptys<\/p>\n Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a pathogenic T cell depleter, completed a Phase 2b trial for the treatment of rheumatoid arthritis and is in a Phase 2 trial for the treatment of ulcerative colitis. The company\u2019s pipeline also includes ANB033, a CD122 antagonist, being studied in celiac disease and ANB101, a BDCA2 modulator, both in Phase 1 trials. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli\u00a0(dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit\u00a0www.AnaptysBio.com<\/a>\u00a0or follow us on\u00a0LinkedIn<\/a>.<\/p>\n Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company. Learn more here<\/a>.<\/p>\n
![\"\"](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/10\/AnaptysBio-Inc-.png\")